Inhibition of CARM1 leads to H3K27ac deletion in the CREBBP/EP300 chromatin binding region, downregulating CREBBP target genes and further inhibiting DLBCL cell growth. The gene discussed is EP300; the disease is diffuse large B-cell lymphoma.